Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesProspect of JAK2 inhibitor therapy in myeloproliferative neoplasms
Expert Review of Anticancer Therapy, 05/19/09
Atallah E et al. - A number of molecules that inhibit JAK2 kinase have been described in the literature, and several are being evaluated in a clinical setting. Here, the authors summarize current clinical experience with JAK2 inhibitors.
Related Articles
Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms
British Journal of Haematology, 11/11/09
Relevance Score: 67%
AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
Blood, 11/09/09
Relevance Score: 67%
Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells
Blood, 11/02/09
Relevance Score: 66%
Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity
Clinical Cancer Research, 11/09/09
Relevance Score: 65%
Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type
Annals of Oncology, 10/29/09
Relevance Score: 44%
Today in Myeloproliferative Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy
Biology of Blood and Marrow Transplantation, 12/16/09
Telomere shortening and chromosomal instability in myelodysplastic syndromes
Genes, Chromosomes and Cancer, 12/16/09
Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells
European Journal of Haematology, 12/11/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Port central venous catheters–associated bloodstream infection during outpatient-based chemotherapyTEST
Medical Oncology, 12/17/09
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiformeTEST
Journal of Neuro-Oncology, 12/17/09
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease
Breast Cancer Research, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor